1life Healthcare (ONEM) 10-Q4 May 222022 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	Apr. 18, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39203
Entity Registrant Name	1LIFE HEALTHCARE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	76-0707204
Entity Address, Address Line One	One Embarcadero Center
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94111
City Area Code	(415)
Local Phone Number	814-0927
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ONEM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		194,047,510
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001404123
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 239,978	$ 341,971
Short-term marketable securities	141,064	111,671
Accounts receivable, net	142,288	103,498
Inventories	6,021	6,065
Prepaid expenses	31,466	28,055
Other current assets	23,311	21,767
Total current assets	584,128	613,027
Long-term marketable securities	47,438	48,296
Restricted cash	3,801	3,801
Property and equipment, net	199,137	193,716
Right-of-use assets	266,592	256,293
Intangible assets, net	341,200	352,158
Goodwill	1,145,094	1,147,464
Other assets	8,639	12,277
Total assets	2,596,029	2,627,032
Current liabilities:
Accounts payable	15,842	18,725
Accrued expenses	73,534	72,672
Deferred revenue, current	64,317	47,928
Operating lease liabilities, current	33,316	31,152
Other current liabilities	34,088	31,632
Total current liabilities	221,097	202,109
Operating lease liabilities, non-current	283,206	269,641
Convertible senior notes	310,313	309,844
Deferred income taxes	67,141	73,875
Deferred revenue, non-current	27,385	29,317
Other non-current liabilities	11,042	13,663
Total liabilities	920,184	898,449
Commitments and contingencies (Note 13)
Stockholders' Equity:
Common stock, $0.001 par value, 1,000,000 and 1,000,000 shares authorized as of March 31, 2022 and December 31, 2021, respectively; 193,483 and 191,722 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	194	193
Additional paid-in capital	2,385,934	2,346,781
Accumulated deficit	(709,057)	(618,198)
Accumulated other comprehensive income	(1,226)	(193)
Total stockholders' equity	1,675,845	1,728,583
Total liabilities and stockholders' equity	$ 2,596,029	$ 2,627,032

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares, issued (in shares)	193,483,000	191,722,000
Common stock, shares, outstanding (in shares)	193,483,000	191,722,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenue:	$ 254,102	$ 121,352
Operating expenses:
Medical claims expense	104,966	0
Cost of care, exclusive of depreciation and amortization shown separately below	101,377	70,092
Sales and marketing	22,459	12,689
General and administrative	97,036	64,345
Depreciation and amortization	20,893	6,607
Total operating expenses	346,731	153,733
Loss from operations	(92,629)	(32,381)
Other income (expense), net:
Interest income	157	105
Interest and other expense	(5,119)	(2,843)
Total other income (expense), net	(4,962)	(2,738)
Loss before income taxes	(97,591)	(35,119)
Provision for (benefit from) income taxes	(6,732)	4,199
Net loss	$ (90,859)	$ (39,318)
Net loss per share — basic (in usd per share)	$ (0.47)	$ (0.29)
Net loss per share — diluted (in usd per share)	$ (0.47)	$ (0.29)
Weighted average common shares outstanding — basic (in shares)	193,019	136,516
Weighted average common shares outstanding — diluted (in shares)	193,019	136,516
Medicare revenue
Net revenue:	$ 127,422	$ 0
Commercial revenue
Net revenue:	$ 126,680	$ 121,352

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (90,859)	$ (39,318)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	(1,033)	12
Comprehensive loss	$ (91,892)	$ (39,306)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect Period of Adoption Adjustment	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative Effect Period of Adoption Adjustment	Accumulated Deficit	Accumulated DeficitCumulative Effect Period of Adoption Adjustment	Accumulated Other Comprehensive Income (Loss)
Beginning balances (in shares) at Dec. 31, 2020			134,472
Beginning balances at Dec. 31, 2020	$ 548,475		$ 134	$ 918,118		$ (369,785)		$ 8
Beginning balances (ASU 2020-06) at Dec. 31, 2020		$ (66,737)			$ (73,393)		$ 6,656
Beginning balances (ASC 326) at Dec. 31, 2020		$ (428)					$ (428)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			2,584
Exercise of stock options	13,479		$ 3	13,476
Issuance of common stock for settlement of RSUs (in shares)			241
Stock-based compensation expense	26,328			26,328
Net unrealized gain (loss) on marketable securities	12							12
Net loss	(39,318)					(39,318)
Ending balances (in shares) at Mar. 31, 2021			137,297
Ending balances at Mar. 31, 2021	481,811		$ 137	884,529		(402,875)		20
Beginning balances (in shares) at Dec. 31, 2021			191,722
Beginning balances at Dec. 31, 2021	$ 1,728,583		$ 193	2,346,781		(618,198)		(193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	579		579
Exercise of stock options	$ 2,235		$ 1	2,234
Issuance of common stock for settlement of RSUs (in shares)			442
Issuance of common stock in acquisition (in shares)			740
Stock-based compensation expense	36,919			36,919
Net unrealized gain (loss) on marketable securities	(1,033)							(1,033)
Net loss	(90,859)					(90,859)
Ending balances (in shares) at Mar. 31, 2022			193,483
Ending balances at Mar. 31, 2022	$ 1,675,845		$ 194	$ 2,385,934		$ (709,057)		$ (1,226)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (90,859)	$ (39,318)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for bad debts	281	(60)
Depreciation and amortization	20,893	6,607
Amortization of debt discount and issuance costs	469	468
Accretion of discounts and amortization of premiums on marketable securities, net	338	199
Reduction of operating lease right-of-use assets	7,950	4,156
Stock-based compensation	36,919	26,328
Deferred income taxes	(6,734)	0
Other non-cash items	211	202
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	(39,071)	8,583
Inventories	44	2,478
Prepaid expenses and other current assets	(999)	(4,870)
Other assets	2,625	(171)
Accounts payable	(680)	(1,248)
Accrued expenses	2,529	8,168
Deferred revenue	14,457	11,050
Operating lease liabilities	(6,687)	(4,434)
Other liabilities	3,230	3,946
Net cash (used in) provided by operating activities	(55,084)	22,084
Cash flows from investing activities:
Purchases of property and equipment, net	(19,225)	(14,808)
Purchases of marketable securities	(54,906)	(69,995)
Proceeds from sales and maturities of marketable securities	25,000	339,000
Net cash (used in) provided by investing activities	(49,131)	254,197
Cash flows from financing activities:
Proceeds from the exercise of stock options	2,235	13,479
Payment of principal portion of finance lease liability	(13)	(14)
Net cash provided by financing activities	2,222	13,465
Net (decrease) increase in cash, cash equivalents and restricted cash	(101,993)	289,746
Cash, cash equivalents and restricted cash at beginning of period	346,054	115,005
Cash, cash equivalents and restricted cash at end of period	244,061	404,751
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	$ 6,837	$ 6,115

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
Nature of the Business and Basis of Presentation	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	Nature of the Business and Basis of Presentation 1Life Healthcare, Inc. (“1Life”) was incorporated in Delaware on July 25, 2002. 1Life’s headquarters are located in San Francisco, California. 1Life has developed a modernized healthcare membership model based on direct consumer enrollment and third-party sponsorship across commercially insured and Medicare populations. Our membership model includes access to 24/7 digital health services paired with in-office care routinely covered by most health care payers, and allows the Company to engage in value-based care across all age groups, including through At-Risk arrangements as defined in Note 2 “Summary of Significant Accounting Policies” with Medicare Advantage payers and the Center for Medicare & Medicaid Services ("CMS"), in which the Company is responsible for managing a range of healthcare services and associated costs of its members. 1Life is also an administrative and managerial services company that provides services pursuant to contracts with physician-owned professional corporations (“One Medical PCs”) that provide medical services virtually and in-office. On September 1, 2021, 1Life completed the acquisition of Iora Health, Inc. ("Iora Health"), a human-centered, value-based primary care group with built-for-purpose technology focused on serving the Medicare population. Iora Health and Iora Senior Health, Inc. (“Iora Senior Health”) are administrative and managerial service companies that provide services pursuant to contracts with physician-owned professional corporations (“Iora PCs”, together with the One Medical PCs, the “PCs”) that provide medical services virtually and in-office. Iora Health is an administrative and managerial services company that provides services pursuant to contracts with Iora Health NE DCE, LLC, a limited liability company that participates in the Center for Medicare and Medicaid Services’ direct contracting model (the “DCE entity”). Iora Health, Iora Senior Health, the Iora PCs and the DCE entity are collectively referred to herein as “Iora”. See Note 7 "Business Combinations" to the unaudited condensed consolidated financial statements. 1Life, Iora Health, Iora Senior Health, the PCs and the DCE entity are collectively referred to herein as the “Company”. 1Life and the One Medical PCs operate under the brand name One Medical. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. GAAP. The accompanying condensed consolidated financial statements include the accounts of 1Life, Iora Health and Iora Senior Health, their wholly owned subsidiaries, and variable interest entities (“VIE”) in which 1Life, Iora Health and Iora Senior Health have an interest and are the primary beneficiaries. See Note 3, “Variable Interest Entities”. All significant intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on February 23, 2022 (the “Form 10-K”). Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, liability for medical claims incurred in the period but not yet reported (“IBNR”), valuation of certain assets and liabilities acquired from business combinations, and stock-based compensation. Actual results could differ from these estimates and may result in material effects on the Company’s operating results and financial position. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for credit losses, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”), which we recognized as Grant income during the three months ended March 31, 2021. The Company did not receive any income grant from the HHS for the three months ended March 31, 2022. See Note 5, "Revenue Recognition". Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases and certain At-Risk arrangements. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 8 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: March 31, December 31, March 31, December 31, 2022 2021 2021 2020 Cash and cash equivalents $ 239,978 $ 341,971 $ 402,721 $ 112,975 Restricted cash, current (included in other current assets) 282 282 119 119 Restricted cash, non-current 3,801 3,801 1,911 1,911 Total cash, cash equivalents, and restricted cash $ 244,061 $ 346,054 $ 404,751 $ 115,005 Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical or Iora facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers. The table below presents the customers or payers that individually represented 10% or more of the Company’s accounts receivable, net balance as of March 31, 2022 and December 31, 2021. March 31, December 31, 2022 2021 Customer F 39 % 38 % Customer I 19 % 23 % * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below presents the customers or payers that individually represented 10% or more of the Company’s net revenue for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, 2022 2021 Customer A * 12 % Customer F * 12 % Customer I 27 % N/A Customer J 18 % N/A * Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are discussed in Note 2 “Summary of Significant Accounting Policies” in Item 15 of its Form 10-K for the fiscal year ended December 31, 2021. Recently Adopted Pronouncements as of March 31, 2022 In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the standard on January 1, 2022 on a prospective basis. The adoption did not have a material impact to the Company's condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted as of March 31, 2022 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of March 31, 2022.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
Variable Interest Entities	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities 1Life, Iora Health and Iora Senior Health's agreements with the PCs generally consist of both Administrative Services Agreements (“ASAs”), which provide for various administrative and management services to be provided by 1Life, Iora Health or Iora Senior Health, respectively, to the PCs, and succession agreements, which provide for transition of ownership of the PCs under certain conditions ("Succession Agreements"). The ASAs typically provide that the term of the arrangements is ten The contractual arrangement to provide management services allows 1Life, Iora Health or Iora Senior Health to direct the economic activities that most significantly affect the PCs. Accordingly, 1Life, Iora Health or Iora Senior Health is the primary beneficiary of the PCs and consolidates the PCs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support 1Life, Iora Health or Iora Senior Health provides to the PCs (e.g. loans) and the provisions of the nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual

Fair Value Measurements and Inv

Fair Value Measurements and Investments	3 Months Ended
Fair Value Measurements and Investments	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	Fair Value Measurements and Investments Fair Value Measurements The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of March 31, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 195,964 $ — $ — $ 195,964 Short-term marketable securities: U.S. Treasury obligations 107,619 — — 107,619 Commercial paper — 33,445 — 33,445 Long-term marketable securities: U.S. Treasury obligations 47,438 — — 47,438 Total financial assets $ 351,021 $ 33,445 $ — $ 384,466 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 315,817 $ — $ — $ 315,817 Short-term marketable securities: U.S. Treasury obligations 58,232 — — 58,232 Foreign government bonds — 5,012 — 5,012 Commercial paper — 48,427 — 48,427 Long-term marketable securities: U.S. Treasury obligations 48,296 — — 48,296 Total financial assets $ 422,345 $ 53,439 $ — $ 475,784 Our financial assets are valued using market prices on both active markets (Level 1) and less active markets (Level 2). Level 1 instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets. Level 2 instrument valuations are obtained from readily available pricing sources for comparable instruments, identical instruments in less active markets, or models using market observable inputs. During the three months ended March 31, 2022 and 2021, there were no transfers between Level 1, Level 2 and Level 3. Valuation of Convertible Senior Notes The Company has $316,250 aggregate principal amount outstanding of 3.0% convertible senior notes due in 2025 (the “2025 Notes”). See Note 9, “Convertible Senior Notes” for details. The fair value of the 2025 Notes was $275,210 and $288,461 as of March 31, 2022 and December 31, 2021, respectively. The fair value was determined based on the closing trading price of the 2025 Notes as of the last day of trading for the period. The fair value of the 2025 Notes is primarily affected by the trading price of the Company's common stock and market interest rates. The fair value of the 2025 Notes is considered a Level 2 measurement as they are not actively traded. Investments At March 31, 2022 and December 31, 2021, the Company’s cash equivalents and marketable securities were as follows: March 31, 2022 Amortized Gross Fair value Cash equivalents: Money market fund $ 195,964 $ — $ 195,964 Total cash equivalents 195,964 — 195,964 Short-term marketable securities: U.S. Treasury obligations 108,020 (401) 107,619 Commercial paper 33,445 — 33,445 Total short-term marketable securities 141,465 (401) 141,064 Long-term marketable securities: U.S. Treasury obligations 48,263 (825) 47,438 Total cash equivalents and marketable securities $ 385,692 $ (1,226) $ 384,466 December 31, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 315,817 $ — $ 315,817 Total cash equivalents 315,817 — 315,817 Short-term marketable securities: U.S. Treasury obligations 58,293 (61) 58,232 Foreign government bonds 5,013 (1) 5,012 Commercial paper 48,427 — 48,427 Total short-term marketable securities 111,733 (62) 111,671 Long-term marketable securities: U.S. Treasury obligations 48,427 (131) 48,296 Total cash equivalents and marketable securities $ 475,977 $ (193) $ 475,784

Revenue Recognition

Revenue Recognition	3 Months Ended
Revenue Recognition	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The following table summarizes the Company’s net revenue by primary source: Three Months Ended March 31, 2022 2021 Net revenue: Capitated revenue $ 124,630 $ — Fee-for-service and other revenue 2,792 — Total Medicare revenue 127,422 — Partnership revenue 60,935 54,931 Net fee-for-service revenue 41,514 44,462 Membership revenue 24,231 20,196 Grant income — 1,763 Total commercial revenue 126,680 121,352 Total net revenue $ 254,102 $ 121,352 Net fee-for-service revenue (previously reported as net patient service revenue) is primarily generated from commercial third-party payers with which the One Medical entities have established contractual billing arrangements. The following table summarizes net fee-for-service revenue by source: Three Months Ended March 31, 2022 2021 Net fee-for-service revenue: Commercial and government third-party payers $ 36,606 $ 42,235 Patients, including self-pay, insurance co-pays and deductibles 4,908 2,227 Net fee-for-service revenue $ 41,514 $ 44,462 The CARES Act was enacted on March 27, 2020 to provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant of $1,763 from the Provider Relief Fund administered by the Health and Human Services ("HHS") during the three months ended March 31, 2021. The Company did not receive any income grants from the HHS for the three months ended March 31, 2022. Management has concluded that the Company met conditions of the grant funds and has recognized it as Grant income for the three months ended March 31, 2021. During the three months ended March 31, 2022, the Company recognized revenue of $19,015, which was included in the beginning deferred revenue balances as of January 1, 2022. During the three months ended March 31, 2021, the Company recognized revenue of $14,321, which was included in the beginning deferred revenue balances as of January 1, 2021. As of March 31, 2022, a total of $5,571 is included within deferred revenue related to variable consideration, of which $4,425 is classified as non-current as it will not be recognized within the next twelve months. The estimate of variable consideration is based on the Company’s assessment of historical, current, and forecasted performance. As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. March 31, December 31, 2022 2021 Balances from contracts with customers: Capitated accounts receivable, net $ 34,083 $ 23,903 All other accounts receivable, net 108,205 79,595 Contract asset (included in other current assets) 382 458 Deferred revenue $ 91,702 $ 77,245 Capitated accounts receivable and payable related to At-Risk arrangements are recorded net in the condensed consolidated balance sheets when a legal right of offset exists. A right of offset exists when all of the following conditions are met: 1) each of two parties (the Company and the third-party payer) owes the other determinable amounts; 2) the reporting party (the Company) has the right to offset the amount owed with the amount owed by the other party (the third-party payer); 3) the reporting party (the Company) intends to offset; and 4) the right of offset is enforceable by law. All of the aforementioned conditions were met as of March 31, 2022. The capitated accounts receivable and payable are recorded at the contract level and consist of the Company’s Capitated Revenue attributed from enrolled At-Risk members less actual paid medical claims expense. If the Capitated Revenue exceeds the actual medical claims expense at the end of the reporting period, such surplus is recorded as capitated accounts receivable within accounts receivable, net in the condensed consolidated balance sheets. If the actual medical claims expense exceeds the Capitated Revenue, such deficit is recorded as capitated accounts payable within other current liabilities in the condensed consolidated balance sheets. As of March 31, 2022, the Company has capitated accounts receivable, net, of $34,083 and capitated accounts payable, net, of $6,132, representing amounts due from and to Medicare Advantage payers and CMS in At-Risk arrangements, respectively. The capitated accounts receivable and payable are presented net of IBNR claims liability and other adjustments. There were no significant prior period adjustments or changes to the assumptions used in estimating the IBNR claims liability as of March 31, 2022. The Company believes the amounts accrued to cover IBNR claims as of March 31, 2022 are adequate. Components of capitated accounts receivable, net is summarized below: March 31, December 31 2022 2021 Capitated accounts receivable $ 72,286 $ 56,384 IBNR claims liability (36,989) (32,320) Other adjustments (1,214) (161) Capitated accounts receivable, net $ 34,083 $ 23,903 Components of capitated accounts payable, net is summarized below: March 31, December 31 2022 2021 Capitated accounts payable $ 4,874 $ 5,483 IBNR claims liability 1,315 1,438 Other adjustments (57) 299 Capitated accounts payable, net $ 6,132 $ 7,220 Activity in IBNR claims liability from December 31, 2021 through March 31, 2022 is summarized below: Amount Balance as of December 31, 2021 $ 33,758 Incurred related to: Current period 102,864 Prior periods 2,102 104,966 Paid related to: Current period (67,755) Prior periods (32,665) (100,420) Balance as of March 31, 2022 $ 38,304 The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of March 31, 2022, is expected to be recognized as follows: Less than Greater Total As of March 31, 2022 $ 15,671 $ 30,279 $ 45,950

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2022
Leases [Abstract]
Leases	Leases Most leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 7 years. Certain lease agreements contain options to terminate the lease before maturity. The Company does not have any lease contracts with the option to purchase as of March 31, 2022. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Certain of the Company’s furniture and fixtures and lab equipment are held under finance leases. Finance-lease-related assets are included in property and equipment, net in the condensed consolidated balance sheets and are immaterial as of March 31, 2022. The components of operating lease costs were as follows: Three Months Ended March 31, 2022 2021 Operating lease costs $ 13,004 $ 7,333 Variable lease costs 2,047 1,311 Total lease costs $ 15,051 $ 8,644 Other information related to leases was as follows: Supplemental Cash Flow Information Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,066 $ 7,855 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 18,249 $ 16,086 Lease Term and Discount Rate March 31, December 31, 2022 2021 Weighted-average remaining lease term (in years) 8.08 8.02 Weighted-average discount rate 6.61 % 6.55 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate. Management determines the appropriate incremental borrowing rates for each of its leases based on the remaining lease term at lease commencement. Future minimum lease payments under non-cancellable operating leases as of March 31, 2022 were as follows (excluding the effect of lease incentives to be received that are recorded in other current assets of $13,990 which serve to reduce total lease payments): March 31, 2022 Remainder of 2022 $ 39,186 2023 55,546 2024 53,831 2025 50,127 2026 46,658 Thereafter 168,984 Total lease payments 414,332 Less: interest (97,810) Total lease liabilities $ 316,522

Business Combinations

Business Combinations	3 Months Ended
Business Combinations	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business CombinationsAcquisition of Iora On September 1, 2021 ("Acquisition Date"), 1Life acquired all outstanding equity and capital stock of Iora Health, a human-centered, value-based primary care group with built-for-purpose technology focused on serving the Medicare population, for an aggregate purchase consideration of $1,424,836, which was paid through the issuance of 1Life common shares with a fair value of $1,313,312, in part by cash of $62,881, and in part by stock options of Iora assumed by 1Life towards pre-combination services of $48,643. The acquisition was accounted for as a business combination. Subsequent to the Acquisition Date, the Company recorded $2,370 decrease to goodwill during the measurement period in the first quarter of 2022. The preliminary purchase price allocations resulted in $1,117,913 of goodwill and $363,031 of acquired identifiable intangible assets related to Iora trade name and contracts in existing geographies valued using the income method. Goodwill recorded in the acquisition is not expected to be deductible for tax purposes. Goodwill was primarily attributable to the planned growth in new geographies, synergies expected to be achieved in the combined operations of 1Life and Iora, and assembled workforce of Iora. The acquisition expanded the Company's reach to become a premier national human-centered, technology-powered, value-based primary care platform across all age groups. The acquisition allows the Company to participate in At-Risk arrangements with Medicare Advantage payers and CMS, in which the Company is responsible for managing a range of healthcare services and associated costs of its members. Preliminary Purchase Price Allocation The purchase price components are summarized in the following table: Consideration in 1Life common stock (1) $ 1,313,312 Cash consideration (2) 62,881 Stock options of Iora assumed by 1Life towards pre-combination services (3) 48,643 Total Purchase Price $ 1,424,836 (1) Represents the fair value of 53,583 shares of 1Life common stock transferred as consideration consisting of 53,146 shares issued and 437 shares to be issued to former Iora shareholders for outstanding Iora capital stock based on 77,687 Iora shares with the Exchange Ratio of 0.69 for a share of Iora and 1Life's stock price of $24.51 as of the closing date. The fair value of the 53,583 shares transferred as consideration was determined on the basis of the closing market price of the Company's common stock one business day prior to the Acquisition Date. (2) Included in the cash consideration are: • $5,993 for the settlement of vested phantom stock awards and cash bonuses contingent on the completion of the merger. Iora's unvested phantom stock awards, to the extent they relate to post-combination services, will be paid out and expensed as they vest subsequent to the acquisition and will be treated as stock-based compensation expense. • $30,253 of loans made by the Company to Iora prior to the Acquisition Date. • $5,391 of repayment of the existing Silicon Valley Bank (“SVB”) loan, which was not legally assumed as part of the merger. • The remainder of the cash consideration primarily relates to transaction expenses incurred by Iora and paid by the Company as of the closing date. (3) Represents the fair value of Iora’s equity awards assumed by 1Life for pre-combination services. Pursuant to the terms of the merger agreement, Iora’s outstanding equity awards that are vested and unvested as of the effective time of the merger were replaced by 1Life equity awards with the same terms and conditions. The vested portion of the fair value of 1Life’s replacement equity awards issued represents consideration transferred, while the unvested portion represents post-combination compensation expense based on the vesting terms of the equity awards. The awards that include a provision for accelerated vesting upon a change of control are included in the vested consideration. The fair value of the stock options of Iora assumed by 1Life was determined by using a Black-Scholes option pricing model with the applicable assumptions as of the Acquisition Date. The fair value of the unvested stock awards, for which post-combination service is required, will be recorded as share-based compensation expense over the respective vesting period of each award. See Note 10, "Stock-Based Compensation". The following table presents the preliminary purchase price allocation recorded in the Company's unaudited condensed consolidated balance sheet as of the Acquisition Date: Cash and cash equivalents acquired $ 17,808 Accounts receivable, net 20,451 Prepaid expenses and other current assets 3,043 Restricted cash 2,069 Property and equipment, net 29,565 Right-of-use assets 70,249 Intangible assets, net 363,031 Other assets (1) 7,405 Total assets 513,621 Accounts payable 1,974 Accrued expenses 9,819 Deferred revenue, current 5,989 Operating lease liabilities, current 6,617 Operating lease liabilities, non-current 63,558 Deferred revenue, non-current 24,316 Deferred income taxes 80,537 Other non-current liabilities (1) 13,888 Total liabilities 206,698 Net assets acquired 306,923 Estimated Merger Consideration 1,424,836 Estimated goodwill attributable to Merger $ 1,117,913 (1) Included in the other assets was an escrow asset of $2,875 related to 1Life common stock held by a third-party escrow agent to be released to the former stockholders of Iora, less any amounts that would be necessary to satisfy any then pending and unsatisfied or unresolved claim for indemnification for any 1Life indemnifiable loss pursuant to the indemnity provisions of the Merger Agreement. A corresponding indemnification liability of $9,600 was recorded in other non-current liabilities in the Company's unaudited condensed consolidated balance sheet. During the three months ended March 31, 2022, a reduction in escrow asset and indemnification liability of $1,013 and $3,383, respectively was recorded as part of the measurement period adjustment. The indemnification asset is subject to remeasurement at each reporting date due to changes to the underlying value of the escrow shares until the shares are released from escrow, with the remeasurement adjustment reported in the Company's condensed consolidated statement of operations as interest and other expense. During the three months ended March 31, 2022, the fair value of the escrow asset had reduced and the unrealized loss recorded was $2,277 for the period. The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of fair values, which were determined primarily using the income method based on estimates and assumptions made by management at the time of the Iora acquisition and are subject to change during the measurement period which is not expected to exceed one year. The primary tasks that are required to be completed include valuation of certain assets and liabilities, including any related tax impacts. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined. The Company recognized a net deferred tax liability of $80,537 in this business combination that is included in long-term liabilities in the accompanying condensed consolidated balance sheet. This primarily related to identified intangible assets recorded in acquisition for which there is no tax basis. Identifiable intangible assets are comprised of the following: Preliminary Fair Value Estimated Useful Life (in years) Intangible Asset: Medicare Advantage contracts - existing geographies $ 298,000 9 CMS Direct Contracting contract - existing geographies 52,000 9 Trade name: Iora 13,031 3 Total $ 363,031 Net tangible assets were valued at their respective carrying amounts as of the Acquisition Date, which approximated their fair values. Medicare Advantage contracts and CMS Direct Contracting contract represent the At-Risk arrangements that Iora has with Medicare Advantage plans or directly with CMS. Trade names represent the Company’s right to the Iora trade names and associated design. Loan Agreement Under the Merger Agreement, 1Life and Iora have also entered into a Loan and Security Agreement on June 21, 2021. See Note 15 "Note Receivable" for more details. Iora had an existing credit facility with SVB, which is referred to as the SVB Facility. The SVB facility of $5,391 was repaid on September 1, 2021, of which $50 is related to the prepayment penalty. Repayment of the existing SVB loan is accounted for as part of the acquisition purchase consideration. Supplemental Unaudited Pro Forma Information The following unaudited pro forma financial information summarizes the combined results of operations for 1Life and Iora as if the companies were combined as of the beginning of fiscal year 2020. The unaudited pro forma information includes transaction and integration costs, adjustments to amortization and depreciation for intangible assets and property and equipment acquired, stock-based compensation costs and tax effects. The table below reflects the impact of material adjustments to the unaudited pro forma results for the three months ended March 31, 2021 that are directly attributable to the acquisition: Three Months Ended March 31, Material Adjustments 2021 (Decrease) / increase to expense as result of transaction costs $ (3,237) (Decrease) / increase to expense as result of amortization and depreciation expenses 11,541 (Decrease) / increase to expense as a result of stock-based compensation costs 698 (Decrease) / increase to expense as result of changes in tax effects $ (4,909) The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of our condensed consolidated results of operations of the combined business had the acquisition actually occurred at the beginning of fiscal year 2020 or the results of our future operations of the combined businesses. Three Months Ended March 31, 2021 Revenue $ 183,620 Net Loss $ (62,374) Other Acquisitions In 2021, the Company completed three other acquisitions for $9,908 of total cash consideration. The acquisitions were each accounted for as business combinations. The Company does not consider these acquisitions to be material, individually or in aggregate, to the Company’s condensed consolidated financial statements. The purchase price allocations resulted in $5,880 of goodwill and $3,921 of acquired identifiable intangible assets related to customer relationships valued using the income method. Intangible assets are being amortized over their respective useful lives of three

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill As of March 31, 2022 and December 31, 2021, goodwill was $1,145,094 and $1,147,464, respectively. Due to the recent decline in the Company's stock price and uncertainties in general economic conditions, the Company considered the recoverability of its goodwill and determined, during three months ended March 31, 2022, there were no events or circumstances that have changed since the last annual test that could more likely than not reduce the fair value of the Company's reporting unit below its carrying value. No goodwill impairments were recorded during the three months ended March 31, 2022. Changes in economic and operating conditions and any further decline in the Company's stock price could result in potential goodwill impairment in future periods. Goodwill balances as of March 31, 2022 and December 31, 2021 were as follows: Goodwill Balance as of December 31, 2021 $ 1,147,464 Measurement period adjustments (2,370) Balance as of March 31, 2022 $ 1,145,094 Intangible Assets The following summarizes the Company’s intangible assets and accumulated amortization as of March 31, 2022: March 31, 2022 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (19,315) $ 278,685 CMS Direct Contracting contract - existing geographies 52,000 (3,370) 48,630 Trade name: Iora 13,031 (2,534) 10,497 Customer relationships 3,921 (533) 3,388 Total intangible assets $ 366,952 $ (25,752) $ 341,200 The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2021: December 31, 2021 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (11,037) $ 286,963 CMS Direct Contracting contract - existing geographies 52,000 (1,926) 50,074 Trade name: Iora 13,031 (1,448) 11,583 Customer relationships 3,921 (383) 3,538 Total intangible assets $ 366,952 $ (14,794) $ 352,158 The Company did not record any amortization expense of intangible assets for the three months ended March 31, 2021. Purchased intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. As of March 31, 2022, estimated future amortization expense related to intangible assets were as follows: March 31, 2022 Remainder of 2022 $ 32,876 2023 43,835 2024 42,356 2025 39,417 2026 39,417 Thereafter 143,299 Total $ 341,200

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
Convertible Senior Notes	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior Notes In May 2020, the Company issued and sold $275,000 aggregate principal amount of 3.0% convertible senior notes due 2025 in a private offering exempt from the registration requirements of the Securities Act of 1933, and in June 2020, the Company issued an additional $41,250 aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment option by the initial purchasers of the notes (the “2025 Notes”). The 2025 Notes are unsecured obligations and bear interest at a fixed rate of 3.0% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2020. The 2025 Notes will mature on June 15, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the debt offering, after deducting the initial purchasers’ commissions and other issuance costs, were $306,868. Each $1 principal amount of the 2025 Notes will initially be convertible into 0.0225052 shares of the Company’s common stock, which is equivalent to an initial conversion price of $44.43 per share, subject to adjustment upon the occurrence of specified events but not for any accrued and unpaid interest. Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity. On or after March 15, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election and in accordance with the terms of the indenture governing the 2025 Notes. If the Company satisfies its conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 trading day observation period. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such a corporate event or notice of redemption, as the case may be. If the Company undergoes a fundamental change prior to the maturity date, holders of the 2025 Notes may require the Company to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if specific corporate events occur prior to the applicable maturity date, the Company will increase the conversion rate for a holder who elects to convert their 2025 Notes in connection with such a corporate event in certain circumstances. The Company may not redeem the 2025 Notes prior to June 20, 2023. The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes. During the three months ended March 31, 2022, the conditions allowing holders of the 2025 Notes to convert have not been met. The 2025 Notes are therefore not convertible as of March 31, 2022 and are classified in long term liabilities in the condensed consolidated balance sheet. The Company incurred issuance costs of $9,374 and amortizes the issuance costs to interest expense over the contractual term of the 2025 Notes at an effective interest rate of 0.65%. The net carrying amount of the 2025 Notes was as follows: March 31, December 31, 2022 2021 Liabilities: Principal $ 316,250 $ 316,250 Unamortized issuance costs (5,937) (6,406) Net carrying amount $ 310,313 $ 309,844 The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended March 31, 2022 2021 Contractual interest expense $ 2,372 $ 2,372 Amortization of issuance costs 469 469 Total interest expense related to the 2025 Notes $ 2,841 $ 2,841

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Incentive Plan The Company has the following stock-based compensation plans: the 2007 Equity Incentive Plan (the “2007 Plan”), the 2017 Equity Incentive Plan (the “2017 Plan”), and the 2020 Equity Incentive Plan (the “2020 Plan”, and, together with the 2007 Plan and the 2017 Plan, the “Plans”). In January 2020, the Company’s stockholders approved the 2020 Plan, which took effect upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The 2020 Plan is intended as the successor to and continuation of the 2007 Plan and the 2017 Plan. The number of shares of common stock reserved for issuance under the Company’s 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021, and continuing through and including January 1, 2030, by 4% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company’s board prior to the applicable January 1st. The number of shares issuable under the Plans is adjusted for capitalization changes, forfeitures, expirations and certain share reacquisitions. The Plan provides for the grants of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), restricted stock awards, and restricted stock unit awards (“RSUs”). ISOs may be granted only to employees, including officers. All other awards may be granted to employees, including officers, non-employee directors and consultants. The 2020 Plan provides that grants of ISOs will be made at no less than the estimated fair value of common stock, as determined by the Board of Directors, at the date of grant. Stock options granted to employees and nonemployees under the Plans generally vest over 4 years. Options granted under the Plans generally expire 10 years after the date of grant. At March 31, 2022, 2,950 shares were available for future grants. 2020 Employee Stock Purchase Plan In January 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The ESPP provides for separate six-month offering periods beginning on May 16 and November 16 of each year. At March 31, 2022, 4,246 shares were available for future issuance. The stock-based compensation expense recognized for the ESPP was $425 and $621 during the three months ended March 31, 2022 and 2021, respectively. Stock Options The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 28,312 $ 19.32 7.57 $ 192,955 Granted 1,819 12.11 Exercised (579) 3.86 Canceled (444) 15.51 Outstanding as of March 31, 2022 29,108 $ 19.24 7.49 $ 79,748 Options exercisable as of March 31, 2022 12,146 $ 5.95 6.08 $ 71,253 Options vested and expected to vest as of March 31, 2022 18,893 $ 8.60 6.83 $ 79,303 At March 31, 2022 and 2021, there was $24,640 and $17,897, respectively, in unrecognized compensation expense related to service-based options, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.6 and 1.9 years, respectively. The fair value of stock option grants with service-based vesting conditions was $11,598 and $12,168 for the three months ended March 31, 2022 and 2021, respectively. Assumed Equity Awards As of the Acquisition Date, the Company assumed Iora’s outstanding equity awards related to stock options and phantom stock. The awards under the assumed equity plan were generally settled as follows: • Options: All Iora options outstanding on the close date were assumed by 1Life and converted into options to acquire shares of 1Life common stock. The vested and unvested options, to the extent related to pre-combination services were included in the consideration transferred. Iora’s unvested options, to the extent they relate to post-combination services, will be expensed as they vest post the acquisition and will be treated as stock-based compensation expense. See Note 7 "Business Combinations". • Phantom stock: Each Iora vested phantom stock award has been settled in cash. Each Iora unvested phantom stock award has been assumed by the Company and converted into the right to receive the unvested phantom cash award. Each unvested phantom cash award will remain subject to the same terms and conditions as were applicable to the underlying unvested phantom stock award immediately prior to the close date. The unvested phantom stock award is considered a liability-classified award as the settlement involves a cash payment upon the dates when these awards vest. The entire vested award and unvested phantom stock, to the extent they relate to pre-combination services, were included in the consideration transferred. Iora’s unvested phantom stock awards, to the extent they relate to post-combination services, will be expensed as they vest post acquisition and will be treated as stock-based compensation expense. See Note 7 "Business Combinations". As of the Acquisition Date, the estimated fair value of the assumed equity awards was $60,856, of which $52,662 was allocated to the purchase price and the balance of $8,194 will be recognized as stock-based compensation expense over the remainder term of the assumed equity awards. The fair value of the assumed equity awards for service rendered through the Acquisition Date was recognized as a component of the acquisition consideration, with the remaining fair value related to post combination services to be recorded as stock-based compensation over the remaining vesting period. Market-based Stock Options During the year ended December 31, 2020, the Board of Directors (“Board”) approved the grant of a long-term market-based stock option (the “Performance Stock Option”) to the Company’s Chief Executive Officer and President. The Performance Stock Option was granted to acquire up to 8,645 shares of the Company’s common stock upon exercise. The Performance Stock Option consists of four separate tranches and each tranche will vest over a seven-year time period and only if the Company’s stock price sustains achievement of pre-determined increases for a period of 90 consecutive calendar days and the Chief Executive Officer remains employed with the Company. The exercise price per share of the Stock Option is the closing price of a share of the Company’s common stock on the date of grant. The vesting of the Performance Stock Option can also be triggered upon a change in control. The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660 As of March 31, 2022, no stock price milestones have been achieved. Consequently, no shares subject to the Performance Stock Option have vested as of the date of this filing. The entire 8,645 shares granted are excluded from options vested and expected to vest from the options activity table presented above. The Company will recognize aggregate stock-based compensation expense of $197,469 over the derived service period of each tranche using the accelerated attribution method as long as the service-based vesting conditions are satisfied. If the market conditions are achieved sooner than the derived service period, the Company will adjust its stock-based compensation to reflect the cumula tive expense associated with the vested awards. The Company recorded stock-based compensation expense of $14,089 and $14,926 related to the award for the three months ended March 31, 2022 and 2021, which is included in general and administrative on the condensed consolidated statements of operations. Unamortized stock-based compensation expense related to the award was $122,863 as of March 31, 2022. Restricted Stock Units The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2021 3,249 $ 27.90 Granted 4,693 11.78 Vested (434) 31.76 Canceled and forfeited (292) 17.78 Unvested and outstanding as of March 31, 2022 7,216 $ 17.60 Stock-Based Compensation Expense Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended March 31, 2022 2021 Sales and marketing $ 943 $ 1,023 General and administrative 35,976 25,305 Total $ 36,919 $ 26,328 A tax benefit of $1,938 and $30,394 for the three months ended March 31, 2022 and 2021, respectively, was included in the Company’s net operating loss carry-forward that could potentially reduce future tax liabilities.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company recorded an income tax benefit of $6,732 and an income tax provision of $4,199 for the three months ended March 31, 2022 and 2021, respectively. This represents an effective tax rate for the respective periods of 6.9% and (12.0)%, respectively. The Company reassessed the ability to realize deferred tax assets by considering the available positive and negative evidence. As of March 31, 2022, the Company maintains a full valuation allowance against its net deferred tax assets. Amortization of book identified intangibles from that acquisition resulted in a decrease to deferred tax liabilities; the associated income tax benefit during the period was $6,745. The effective tax rate differs in 2022 from the federal statutory rate due to the change in need for valuation allowance and amortization of identified intangibles. The effective tax rate differs in 2021 from the federal statutory rate due to increased taxable income in profitable entities and the change in need for valuation allowance.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share were calculated as follows: Three Months Ended March 31, 2022 2021 Numerator: Net loss $ (90,859) $ (39,318) Denominator: Weighted average common shares outstanding — basic and diluted 193,019 136,516 Net loss per share — basic and diluted $ (0.47) $ (0.29) The Company’s potentially dilutive securities, which include stock options, unvested RSUs, 2025 Notes and shares held in special indemnity escrow account in connection with Iora acquisition, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Options to purchase common stock 29,108 26,160 Unvested restricted stock 7,207 1,847 2025 Notes (1) 7,117 7,117 Shares held in special indemnity escrow account in connection with Iora acquisition 405 — 43,837 35,124

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of March 31, 2022 and December 31, 2021, the Company has not incurred any material costs as a result of such indemnifications. Legal Matters In May 2018, a class action complaint was filed by two former members against the Company in the Superior Court of California for the County of San Francisco, or the Court, alleging that the Company made certain misrepresentations resulting in them paying the Annual Membership Fee, or AMF, in violation of California’s Consumers Legal Remedies Act, California’s False Advertising Law and California’s Unfair Competition Law, and seeking damages and injunctive relief. Following certain trial court proceedings and certain appeals, arbitration proceedings, and court-ordered mediation proceedings, in June 2021, the parties filed a joint notice of settlement and request for a six month stay before the appellate court in light of reaching a settlement in principle. The parties later executed a class action settlement agreement and release effective June 30, 2021, which requires trial court approval. A preliminary class settlement approval hearing was scheduled to take place in August 2021, but the trial court requested supplemental briefing and vacated the previously scheduled hearing. Plaintiffs filed their supplemental brief and supporting documents on October 12, 2021. The trial court granted the motion for preliminary approval on November 12, 2021. Under the terms of the settlement and the trial court’s order, the settlement will proceed to the class notice phase, which is expected to happen in early 2022. The final approval hearing on the settlement is currently set for July 25, 2022. The settlement amount of $11,500 was recorded as other current liabilities in the condensed consolidated balance sheets as of June 30, 2021. The Company's insurers committed to pay $5,950 towards the settlement amount. The settlement amount, net of expected insurance recovery, of which $5,550 was recorded as general and administrative expenses in the condensed consolidated statements of operations for the three months ended June 30, 2021. Class payout is expected to occur in 2022. There was no material change to the liability amount or any incremental expenses incurred during the three months ended March 31, 2022. Government Inquiries and Investigations In March 2021, the Company received (i) requests for information and documents from the United States House Select Subcommittee on the Coronavirus Crisis, (ii) a request for information from the California Attorney General and the Alameda County District Attorney’s Office and (iii) a request for information and documents from the Federal Trade Commission relating to the Company’s provision of COVID-19 vaccinations. The Company has also received inquiries from state and local public health departments regarding its vaccine administration practices and has and may continue to receive additional requests for information from other governmental agencies relating to its provision of COVID-19 vaccinations. The Company is cooperating with these requests as well as requests received from other governmental agencies, including with respect to the Company's compensation practices and membership generation during the relevant periods. The majority staff of the Subcommittee released a memorandum of findings in December 2021. No further disclosures, testimony or other responses have been requested by the Subcommittee. In addition, in February 2022, the Federal Trade Commission advised us that they were closing their inquiry on our provision of COVID-19 vaccinations. The Company is unable to predict the outcomes or timeline of the residual government inquiries or if any additional requests, inquiries, investigations or other government actions may arise relating to such circumstances. Legal fees have been recorded as general and administrative expenses in the consolidated statements of operations. Sales and Use Tax During 2017 and 2018, a state jurisdiction engaged in an audit of 1Life’s sales and use tax records applicable to that jurisdiction from March 2011 through February 2017. The Company disputed the finding representing the majority of the state's proposed audit change and successfully overturned the sales tax assessment resulting from the audit in December 2021. As of March 31, 2022, the audit was closed and the payment remitted was not material. In addition, from time to time, the Company has been and may be involved in various legal proceedings arising in the ordinary course of business. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its consolidated financial position, results of operations or cash flows.

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsCertain of the Company’s investors are also affiliated with customers of the Company. Revenue recognized under contractual obligations from such customers was immaterial for the three months ended March 31, 2022 and March 31, 2021, respectively. The outstanding receivable balance from such customers was immaterial as of March 31, 2022 and December 31, 2021, respectively.

Note Receivable

Note Receivable	3 Months Ended
Note Receivable	Mar. 31, 2022
Receivables [Abstract]
Note Receivable	Note ReceivableIn connection with the Iora acquisition, on June 21, 2021, 1Life and Iora entered into a loan agreement under which the Company may advance secured loans to Iora to fund working capital, at Iora's request from time to time, in outstanding amounts not to exceed $75,000 in the aggregate. Amounts drawn under the loan agreement are secured by all assets of Iora and were subordinated to Iora's obligations under its then-existing credit facility with SVB. The loan agreement is effective through the maturity date of borrowed amounts under the loan agreement. Such maturity date is the later of 90 days following the earliest of certain maturity dates set forth in the SVB Facility. Amounts drawn bear interest at a rate equal to 10% per year, payable monthly. As of the Acquisition Date, there was $30,000 drawn and outstanding under the loan agreement. Pursuant to the consummation of Iora's acquisition by 1Life, this note receivable was eliminated as part of intercompany eliminations. $30,253 of note receivable including accrued interests prior to the Acquisition Date was treated as purchase consideration. See Note 7 "Business Combinations" for additional details.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. GAAP. The accompanying condensed consolidated financial statements include the accounts of 1Life, Iora Health and Iora Senior Health, their wholly owned subsidiaries, and variable interest entities (“VIE”) in which 1Life, Iora Health and Iora Senior Health have an interest and are the primary beneficiaries. See Note 3, “Variable Interest Entities”. All significant intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on February 23, 2022 (the “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, liability for medical claims incurred in the period but not yet reported (“IBNR”), valuation of certain assets and liabilities acquired from business combinations, and stock-based compensation. Actual results could differ from these estimates and may result in material effects on the Company’s operating results and financial position. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for credit losses, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”), which we recognized as Grant income during the three months ended March 31, 2021. The Company did not receive any income grant from the HHS for the three months ended March 31, 2022. See Note 5, "Revenue Recognition".
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases and certain At-Risk arrangements. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 8 years.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical or Iora facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers.
Recently Adopted Pronouncements as of March 31, 2022	Recently Adopted Pronouncements as of March 31, 2022 In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the standard on January 1, 2022 on a prospective basis. The adoption did not have a material impact to the Company's condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted as of March 31, 2022	Recently Issued Accounting Pronouncements Not Yet Adopted as of March 31, 2022 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of March 31, 2022.

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Tables)	3 Months Ended
Nature of the Business and Basis of Presentation (Tables)	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: March 31, December 31, March 31, December 31, 2022 2021 2021 2020 Cash and cash equivalents $ 239,978 $ 341,971 $ 402,721 $ 112,975 Restricted cash, current (included in other current assets) 282 282 119 119 Restricted cash, non-current 3,801 3,801 1,911 1,911 Total cash, cash equivalents, and restricted cash $ 244,061 $ 346,054 $ 404,751 $ 115,005
Summary of Customers Representing 10% or More of Accounts Receivables	The table below presents the customers or payers that individually represented 10% or more of the Company’s accounts receivable, net balance as of March 31, 2022 and December 31, 2021. March 31, December 31, 2022 2021 Customer F 39 % 38 % Customer I 19 % 23 % * Represents percentages below 10% of the Company’s accounts receivable in the period.
Summary of Customers Representing 10% or More of Net Revenue	The table below presents the customers or payers that individually represented 10% or more of the Company’s net revenue for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, 2022 2021 Customer A * 12 % Customer F * 12 % Customer I 27 % N/A Customer J 18 % N/A * Represents percentages below 10% of the Company’s net revenue in the period.

Fair Value Measurements and I_2

Fair Value Measurements and Investments (Tables)	3 Months Ended
Fair Value Measurements and Investments (Tables)	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of March 31, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 195,964 $ — $ — $ 195,964 Short-term marketable securities: U.S. Treasury obligations 107,619 — — 107,619 Commercial paper — 33,445 — 33,445 Long-term marketable securities: U.S. Treasury obligations 47,438 — — 47,438 Total financial assets $ 351,021 $ 33,445 $ — $ 384,466 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 315,817 $ — $ — $ 315,817 Short-term marketable securities: U.S. Treasury obligations 58,232 — — 58,232 Foreign government bonds — 5,012 — 5,012 Commercial paper — 48,427 — 48,427 Long-term marketable securities: U.S. Treasury obligations 48,296 — — 48,296 Total financial assets $ 422,345 $ 53,439 $ — $ 475,784
Components of Cash Equivalents and Short-term Marketable Securities	At March 31, 2022 and December 31, 2021, the Company’s cash equivalents and marketable securities were as follows: March 31, 2022 Amortized Gross Fair value Cash equivalents: Money market fund $ 195,964 $ — $ 195,964 Total cash equivalents 195,964 — 195,964 Short-term marketable securities: U.S. Treasury obligations 108,020 (401) 107,619 Commercial paper 33,445 — 33,445 Total short-term marketable securities 141,465 (401) 141,064 Long-term marketable securities: U.S. Treasury obligations 48,263 (825) 47,438 Total cash equivalents and marketable securities $ 385,692 $ (1,226) $ 384,466 December 31, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 315,817 $ — $ 315,817 Total cash equivalents 315,817 — 315,817 Short-term marketable securities: U.S. Treasury obligations 58,293 (61) 58,232 Foreign government bonds 5,013 (1) 5,012 Commercial paper 48,427 — 48,427 Total short-term marketable securities 111,733 (62) 111,671 Long-term marketable securities: U.S. Treasury obligations 48,427 (131) 48,296 Total cash equivalents and marketable securities $ 475,977 $ (193) $ 475,784

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
Revenue Recognition (Tables)	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Net Revenue	The following table summarizes the Company’s net revenue by primary source: Three Months Ended March 31, 2022 2021 Net revenue: Capitated revenue $ 124,630 $ — Fee-for-service and other revenue 2,792 — Total Medicare revenue 127,422 — Partnership revenue 60,935 54,931 Net fee-for-service revenue 41,514 44,462 Membership revenue 24,231 20,196 Grant income — 1,763 Total commercial revenue 126,680 121,352 Total net revenue $ 254,102 $ 121,352
Summary of Net Patient Service Revenue by Source	The following table summarizes net fee-for-service revenue by source: Three Months Ended March 31, 2022 2021 Net fee-for-service revenue: Commercial and government third-party payers $ 36,606 $ 42,235 Patients, including self-pay, insurance co-pays and deductibles 4,908 2,227 Net fee-for-service revenue $ 41,514 $ 44,462
Schedule of Contract Assets and Deferred Revenue	As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. March 31, December 31, 2022 2021 Balances from contracts with customers: Capitated accounts receivable, net $ 34,083 $ 23,903 All other accounts receivable, net 108,205 79,595 Contract asset (included in other current assets) 382 458 Deferred revenue $ 91,702 $ 77,245
Schedule of Capitated Accounts Receivable, Net	Components of capitated accounts receivable, net is summarized below: March 31, December 31 2022 2021 Capitated accounts receivable $ 72,286 $ 56,384 IBNR claims liability (36,989) (32,320) Other adjustments (1,214) (161) Capitated accounts receivable, net $ 34,083 $ 23,903
Schedule of Capitated Accounts Payable	Components of capitated accounts payable, net is summarized below: March 31, December 31 2022 2021 Capitated accounts payable $ 4,874 $ 5,483 IBNR claims liability 1,315 1,438 Other adjustments (57) 299 Capitated accounts payable, net $ 6,132 $ 7,220
Activity in IBNR Claims Liability	Activity in IBNR claims liability from December 31, 2021 through March 31, 2022 is summarized below: Amount Balance as of December 31, 2021 $ 33,758 Incurred related to: Current period 102,864 Prior periods 2,102 104,966 Paid related to: Current period (67,755) Prior periods (32,665) (100,420) Balance as of March 31, 2022 $ 38,304
Schedule of Remaining Performance Obligation	The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of March 31, 2022, is expected to be recognized as follows: Less than Greater Total As of March 31, 2022 $ 15,671 $ 30,279 $ 45,950

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2022
Leases [Abstract]
Components of Operating Lease Costs	The components of operating lease costs were as follows: Three Months Ended March 31, 2022 2021 Operating lease costs $ 13,004 $ 7,333 Variable lease costs 2,047 1,311 Total lease costs $ 15,051 $ 8,644
Supplemental Cash Flow Information	Supplemental Cash Flow Information Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,066 $ 7,855 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 18,249 $ 16,086
Lease Term and Discount Rate	Lease Term and Discount Rate March 31, December 31, 2022 2021 Weighted-average remaining lease term (in years) 8.08 8.02 Weighted-average discount rate 6.61 % 6.55 %
Future Minimum Lease Payments Under Non-cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of March 31, 2022 were as follows (excluding the effect of lease incentives to be received that are recorded in other current assets of $13,990 which serve to reduce total lease payments): March 31, 2022 Remainder of 2022 $ 39,186 2023 55,546 2024 53,831 2025 50,127 2026 46,658 Thereafter 168,984 Total lease payments 414,332 Less: interest (97,810) Total lease liabilities $ 316,522

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
Business Combinations (Tables)	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Purchase Price Components	The purchase price components are summarized in the following table: Consideration in 1Life common stock (1) $ 1,313,312 Cash consideration (2) 62,881 Stock options of Iora assumed by 1Life towards pre-combination services (3) 48,643 Total Purchase Price $ 1,424,836 (1) Represents the fair value of 53,583 shares of 1Life common stock transferred as consideration consisting of 53,146 shares issued and 437 shares to be issued to former Iora shareholders for outstanding Iora capital stock based on 77,687 Iora shares with the Exchange Ratio of 0.69 for a share of Iora and 1Life's stock price of $24.51 as of the closing date. The fair value of the 53,583 shares transferred as consideration was determined on the basis of the closing market price of the Company's common stock one business day prior to the Acquisition Date. (2) Included in the cash consideration are: • $5,993 for the settlement of vested phantom stock awards and cash bonuses contingent on the completion of the merger. Iora's unvested phantom stock awards, to the extent they relate to post-combination services, will be paid out and expensed as they vest subsequent to the acquisition and will be treated as stock-based compensation expense. • $30,253 of loans made by the Company to Iora prior to the Acquisition Date. • $5,391 of repayment of the existing Silicon Valley Bank (“SVB”) loan, which was not legally assumed as part of the merger. • The remainder of the cash consideration primarily relates to transaction expenses incurred by Iora and paid by the Company as of the closing date. (3) Represents the fair value of Iora’s equity awards assumed by 1Life for pre-combination services. Pursuant to the terms of the merger agreement, Iora’s outstanding equity awards that are vested and unvested as of the effective time of the merger were replaced by 1Life equity awards with the same terms and conditions. The vested portion of the fair value of 1Life’s replacement equity awards issued represents consideration transferred, while the unvested portion represents post-combination compensation expense based on the vesting terms of the equity awards. The awards that include a provision for accelerated vesting upon a change of control are included in the vested consideration. The fair value of the stock options of Iora assumed by 1Life was determined by using a Black-Scholes option pricing model with the applicable assumptions as of the Acquisition Date. The fair value of the unvested stock awards, for which post-combination service is required, will be recorded as share-based compensation expense over the respective vesting period of each award. See Note 10, "Stock-Based Compensation".
Preliminary Purchase Allocation	Cash and cash equivalents acquired $ 17,808 Accounts receivable, net 20,451 Prepaid expenses and other current assets 3,043 Restricted cash 2,069 Property and equipment, net 29,565 Right-of-use assets 70,249 Intangible assets, net 363,031 Other assets (1) 7,405 Total assets 513,621 Accounts payable 1,974 Accrued expenses 9,819 Deferred revenue, current 5,989 Operating lease liabilities, current 6,617 Operating lease liabilities, non-current 63,558 Deferred revenue, non-current 24,316 Deferred income taxes 80,537 Other non-current liabilities (1) 13,888 Total liabilities 206,698 Net assets acquired 306,923 Estimated Merger Consideration 1,424,836 Estimated goodwill attributable to Merger $ 1,117,913 (1) Included in the other assets was an escrow asset of $2,875 related to 1Life common stock held by a third-party escrow agent to be released to the former stockholders of Iora, less any amounts that would be necessary to satisfy any then pending and unsatisfied or unresolved claim for indemnification for any 1Life indemnifiable loss pursuant to the indemnity provisions of the Merger Agreement. A corresponding indemnification liability of $9,600 was recorded in other non-current liabilities in the Company's unaudited condensed consolidated balance sheet. During the three months ended March 31, 2022, a reduction in escrow asset and indemnification liability of $1,013 and $3,383, respectively was recorded as part of the measurement period adjustment. The indemnification asset is subject to remeasurement at each reporting date due to changes to the underlying value of the escrow shares until the shares are released from escrow, with the remeasurement adjustment reported in the Company's condensed consolidated statement of operations as interest and other expense. During the three months ended March 31, 2022, the fair value of the escrow asset had reduced and the unrealized loss recorded was $2,277 for the period.
Identifiable Intangible Assets Acquired	Identifiable intangible assets are comprised of the following: Preliminary Fair Value Estimated Useful Life (in years) Intangible Asset: Medicare Advantage contracts - existing geographies $ 298,000 9 CMS Direct Contracting contract - existing geographies 52,000 9 Trade name: Iora 13,031 3 Total $ 363,031
Material Adjustments to the Unaudited Pro Forma Results	The table below reflects the impact of material adjustments to the unaudited pro forma results for the three months ended March 31, 2021 that are directly attributable to the acquisition: Three Months Ended March 31, Material Adjustments 2021 (Decrease) / increase to expense as result of transaction costs $ (3,237) (Decrease) / increase to expense as result of amortization and depreciation expenses 11,541 (Decrease) / increase to expense as a result of stock-based compensation costs 698 (Decrease) / increase to expense as result of changes in tax effects $ (4,909)
Unaudited Pro Forma Information	The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of our condensed consolidated results of operations of the combined business had the acquisition actually occurred at the beginning of fiscal year 2020 or the results of our future operations of the combined businesses. Three Months Ended March 31, 2021 Revenue $ 183,620 Net Loss $ (62,374)

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
Goodwill and Intangible Assets (Tables)	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill balances as of March 31, 2022 and December 31, 2021 were as follows: Goodwill Balance as of December 31, 2021 $ 1,147,464 Measurement period adjustments (2,370) Balance as of March 31, 2022 $ 1,145,094
Schedule of Intangible Assets and Accumulated Amortization	The following summarizes the Company’s intangible assets and accumulated amortization as of March 31, 2022: March 31, 2022 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (19,315) $ 278,685 CMS Direct Contracting contract - existing geographies 52,000 (3,370) 48,630 Trade name: Iora 13,031 (2,534) 10,497 Customer relationships 3,921 (533) 3,388 Total intangible assets $ 366,952 $ (25,752) $ 341,200 The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2021: December 31, 2021 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (11,037) $ 286,963 CMS Direct Contracting contract - existing geographies 52,000 (1,926) 50,074 Trade name: Iora 13,031 (1,448) 11,583 Customer relationships 3,921 (383) 3,538 Total intangible assets $ 366,952 $ (14,794) $ 352,158
Estimated Future Amortization Expense of Intangible Assets	As of March 31, 2022, estimated future amortization expense related to intangible assets were as follows: March 31, 2022 Remainder of 2022 $ 32,876 2023 43,835 2024 42,356 2025 39,417 2026 39,417 Thereafter 143,299 Total $ 341,200

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
Convertible Senior Notes (Tables)	Mar. 31, 2022
Debt Disclosure [Abstract]
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the 2025 Notes was as follows: March 31, December 31, 2022 2021 Liabilities: Principal $ 316,250 $ 316,250 Unamortized issuance costs (5,937) (6,406) Net carrying amount $ 310,313 $ 309,844
Summary of Interest Expense Recognized Related to Convertible Senior Notes	The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended March 31, 2022 2021 Contractual interest expense $ 2,372 $ 2,372 Amortization of issuance costs 469 469 Total interest expense related to the 2025 Notes $ 2,841 $ 2,841

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 28,312 $ 19.32 7.57 $ 192,955 Granted 1,819 12.11 Exercised (579) 3.86 Canceled (444) 15.51 Outstanding as of March 31, 2022 29,108 $ 19.24 7.49 $ 79,748 Options exercisable as of March 31, 2022 12,146 $ 5.95 6.08 $ 71,253 Options vested and expected to vest as of March 31, 2022 18,893 $ 8.60 6.83 $ 79,303
Schedule of Additional Information Relating to Tranche	The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660
Summary of RSU Activity	The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2021 3,249 $ 27.90 Granted 4,693 11.78 Vested (434) 31.76 Canceled and forfeited (292) 17.78 Unvested and outstanding as of March 31, 2022 7,216 $ 17.60
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended March 31, 2022 2021 Sales and marketing $ 943 $ 1,023 General and administrative 35,976 25,305 Total $ 36,919 $ 26,328

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share were calculated as follows: Three Months Ended March 31, 2022 2021 Numerator: Net loss $ (90,859) $ (39,318) Denominator: Weighted average common shares outstanding — basic and diluted 193,019 136,516 Net loss per share — basic and diluted $ (0.47) $ (0.29)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Options to purchase common stock 29,108 26,160 Unvested restricted stock 7,207 1,847 2025 Notes (1) 7,117 7,117 Shares held in special indemnity escrow account in connection with Iora acquisition 405 — 43,837 35,124

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022
Minimum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents	1 year
Maximum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents	8 years

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 239,978	$ 341,971	$ 402,721	$ 112,975
Restricted cash, current (included in other current assets)	282	282	119	119
Restricted cash, non-current	3,801	3,801	1,911	1,911
Total cash, cash equivalents, and restricted cash	$ 244,061	$ 346,054	$ 404,751	$ 115,005

Nature of the Business and Ba_5

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Accounts Receivables (Details) - Customer Concentration Risk - Accounts Receivable, Net	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Customer F
Product Information [Line Items]
Concentration risk, percentage	39.00%	38.00%
Customer I
Product Information [Line Items]
Concentration risk, percentage	19.00%	23.00%

Nature of the Business and Ba_6

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Net Revenue (Details) - Customer Concentration Risk - Net Revenue	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Customer A
Product Information [Line Items]
Concentration risk, percentage		12.00%
Customer F
Product Information [Line Items]
Concentration risk, percentage		12.00%
Customer I
Product Information [Line Items]
Concentration risk, percentage	27.00%
Customer J
Product Information [Line Items]
Concentration risk, percentage	18.00%

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Current assets	$ 584,128	$ 613,027
Current liabilities	$ 221,097	202,109
Variable Interest Entity, Primary Beneficiary \| PCs
Variable Interest Entity [Line Items]
Term of arrangement, renewal period	1 year
Current assets	$ 136,405	129,474
Current liabilities	$ 122,520	$ 115,744
Variable Interest Entity, Primary Beneficiary \| PCs \| Minimum
Variable Interest Entity [Line Items]
Term of arrangement, period	10 years
Variable Interest Entity, Primary Beneficiary \| PCs \| Maximum
Variable Interest Entity [Line Items]
Term of arrangement, period	20 years

Fair Value Measurements and I_3

Fair Value Measurements and Investments - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 141,064	$ 111,671
U.S. Treasury obligations \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	107,619	58,232
U.S. Treasury obligations \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,438	48,296
Foreign government bonds \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Commercial paper \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,445	48,427
Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	195,964	315,817
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	384,466	475,784
Recurring \| U.S. Treasury obligations \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	107,619	58,232
Recurring \| U.S. Treasury obligations \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,438	48,296
Recurring \| Foreign government bonds \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Recurring \| Commercial paper \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,445	48,427
Recurring \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	195,964	315,817
Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	351,021	422,345
Recurring \| Level 1 \| U.S. Treasury obligations \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	107,619	58,232
Recurring \| Level 1 \| U.S. Treasury obligations \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	47,438	48,296
Recurring \| Level 1 \| Foreign government bonds \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring \| Level 1 \| Commercial paper \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 1 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	195,964	315,817
Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	33,445	53,439
Recurring \| Level 2 \| U.S. Treasury obligations \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 2 \| U.S. Treasury obligations \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 2 \| Foreign government bonds \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Recurring \| Level 2 \| Commercial paper \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,445	48,427
Recurring \| Level 2 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0
Recurring \| Level 3 \| U.S. Treasury obligations \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 3 \| U.S. Treasury obligations \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 3 \| Foreign government bonds \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring \| Level 3 \| Commercial paper \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring \| Level 3 \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0	$ 0

Fair Value Measurements and I_4

Fair Value Measurements and Investments - Additional Information (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2020	May 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	$ 316,250	$ 316,250
Interest rate	3.00%		3.00%	3.00%
Convertible notes fair value	$ 275,210	$ 288,461

Fair Value Measurements and I_5

Fair Value Measurements and Investments - Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	$ 239,978	$ 341,971	$ 402,721	$ 112,975
Marketable securities, Gross unrealized gains (losses)	(1,226)	(193)
Total cash equivalents and marketable securities, Amortized cost	385,692	475,977
Total cash equivalents and marketable securities, Fair value	384,466	475,784
Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	141,465	111,733
Marketable securities, Gross unrealized gains (losses)	(401)	(62)
Marketable securities, Fair value	141,064	111,671
U.S. Treasury obligations \| Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	108,020	58,293
Marketable securities, Gross unrealized gains (losses)	(401)	(61)
Marketable securities, Fair value	107,619	58,232
U.S. Treasury obligations \| Long-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	48,263	48,427
Marketable securities, Gross unrealized gains (losses)	(825)	(131)
Marketable securities, Fair value	47,438	48,296
Foreign government bonds \| Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost		5,013
Marketable securities, Gross unrealized gains (losses)		(1)
Marketable securities, Fair value		5,012
Commercial paper \| Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	33,445	48,427
Marketable securities, Gross unrealized gains (losses)	0	0
Marketable securities, Fair value	33,445	48,427
Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	195,964	315,817
Cash equivalents, Fair value	195,964	315,817
Money market fund
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	195,964	315,817
Cash equivalents, Fair value	$ 195,964	$ 315,817

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue:	$ 254,102	$ 121,352
Medicare revenue
Disaggregation of Revenue [Line Items]
Net revenue:	127,422	0
Capitated revenue
Disaggregation of Revenue [Line Items]
Net revenue:	124,630	0
Fee-for-service and other revenue
Disaggregation of Revenue [Line Items]
Net revenue:	2,792	0
Commercial revenue
Disaggregation of Revenue [Line Items]
Net revenue:	126,680	121,352
Partnership revenue
Disaggregation of Revenue [Line Items]
Net revenue:	60,935	54,931
Net fee-for-service revenue
Disaggregation of Revenue [Line Items]
Net revenue:	41,514	44,462
Membership revenue
Disaggregation of Revenue [Line Items]
Net revenue:	24,231	20,196
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue:	$ 0	$ 1,763

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Net Patient Service Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue:	$ 254,102	$ 121,352
Net fee-for-service revenue
Disaggregation of Revenue [Line Items]
Net revenue:	41,514	44,462
Commercial and government third-party payers \| Commercial and government third-party payers
Disaggregation of Revenue [Line Items]
Net revenue:	36,606	42,235
Patients, including self-pay, insurance co-pays and deductibles \| Patients, including self-pay, insurance co-pays and deductibles
Disaggregation of Revenue [Line Items]
Net revenue:	$ 4,908	$ 2,227

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ 254,102	$ 121,352
Contract with customer, liability, revenue recognized	19,015	14,321
Deferred revenue recognized related to variable consideration	5,571
Contract with customer liability related to variable consideration non-current	4,425
Accounts receivable, net	142,288		$ 103,498
Capitated accounts payable, net	6,132		7,220
Capitated accounts receivable, net
Disaggregation of Revenue [Line Items]
Accounts receivable, net	34,083		$ 23,903
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue	0	$ 1,763
Grant Income \| CARES Act \| COVID-19
Disaggregation of Revenue [Line Items]
Net revenue	$ 0

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 142,288	$ 103,498
Contract asset (included in other current assets)	382	458
Deferred revenue	91,702	77,245
Capitated accounts receivable, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	34,083	23,903
All other accounts receivable, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 108,205	$ 79,595

Revenue Recognition - Capitated

Revenue Recognition - Capitated Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounts Receivable, After Allowance For Credit Loss [Roll Forward]
IBNR claims liability	$ (38,304)	$ (33,758)
Accounts receivable, net	142,288	103,498
Capitated accounts receivable
Accounts Receivable, After Allowance For Credit Loss [Roll Forward]
Accounts receivable	72,286	56,384
IBNR claims liability	(36,989)	(32,320)
Other adjustments	(1,214)	(161)
Accounts receivable, net	$ 34,083	$ 23,903

Revenue Recognition - Capitat_2

Revenue Recognition - Capitated Accounts Payable, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Capitated accounts payable	$ 4,874	$ 5,483
IBNR claims liability	1,315	1,438
Other adjustments	(57)	299
Capitated accounts payable, net	$ 6,132	$ 7,220

Revenue Recognition - Activity

Revenue Recognition - Activity in IBNR Claims (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance at beginning of period	$ 33,758
Incurred related to:
Current period	102,864
Prior periods	2,102
Incurred	104,966
Paid related to:
Current period	(67,755)
Prior periods	(32,665)
Paid	(100,420)
Balance at end of period	$ 38,304

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Remaining Performance Obligation (Details) $ in Thousands	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 45,950
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 15,671
Revenue remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 30,279
Revenue remaining performance obligation, expected timing of satisfaction, period

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	Mar. 31, 2022USD ($)
Prepaid Expenses and Other Current Assets
Lessee, Lease, Description [Line Items]
Lease incentives	$ 13,990
Minimum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	7 years

Leases - Components of Operatin

Leases - Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease costs	$ 13,004	$ 7,333
Variable lease costs	2,047	1,311
Total lease costs	$ 15,051	$ 8,644

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 12,066	$ 7,855
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 18,249	$ 16,086

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	8 years 29 days	8 years 7 days
Weighted-average discount rate	6.61%	6.55%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
Remainder of 2022	$ 39,186
2023	55,546
2024	53,831
2025	50,127
2026	46,658
Thereafter	168,984
Total lease payments	414,332
Less: interest	(97,810)
Total lease liabilities	$ 316,522

Business Combinations - Acquisi

Business Combinations - Acquisition of Iora, Additional Information (Details) - USD ($) $ in Thousands	Sep. 01, 2021	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Measurement period adjustments		$ (2,370)
Goodwill		$ 1,145,094	$ 1,147,464
Iora
Business Acquisition [Line Items]
Aggregate purchase consideration	$ 1,424,836
Cash consideration	62,881
Measurement period adjustments	(2,370)
Goodwill	1,117,913
Acquired intangibles	363,031
Deferred tax liability	80,537
Iora \| Stock Options
Business Acquisition [Line Items]
Common stock and stock options assumed	48,643
Iora \| Common Stock
Business Acquisition [Line Items]
Common stock and stock options assumed	$ 1,313,312

Business Combinations - Purchas

Business Combinations - Purchase Price Components (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 01, 2021	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock, shares issued		193,483,000	191,722,000
Iora
Business Acquisition [Line Items]
Common stock, shares issued	77,687,000
Iora
Business Acquisition [Line Items]
Cash consideration	$ 62,881
Total Purchase Price	$ 1,424,836
Number of shares to be issued or reserved for issuance	53,146,000
Number of shares issued	53,583,000
Number of shares issuable	437,000
Number of shares to be converted per each acquiree share	0.69
Stock price (in usd per share)	$ 24.51
Payment for settlement of vested phantom stock awards and cash bonuses contingent on completion of the merger	$ 5,993
Loan advances	30,253
Iora \| Credit Facility
Business Acquisition [Line Items]
Debt assumed and repaid	5,391
Iora \| Stock Options
Business Acquisition [Line Items]
Common stock and stock options assumed	48,643
Iora \| Common Stock
Business Acquisition [Line Items]
Common stock and stock options assumed	$ 1,313,312

Business Combinations - Prelimi

Business Combinations - Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Sep. 01, 2021
Business Acquisition [Line Items]
Estimated goodwill attributable to Merger		$ 1,145,094	$ 1,147,464
Iora
Business Acquisition [Line Items]
Cash and cash equivalents acquired				$ 17,808
Accounts receivable, net				20,451
Prepaid expenses and other current assets				3,043
Restricted cash				2,069
Property and equipment, net				29,565
Right-of-use assets				70,249
Intangible assets, net				363,031
Other assets				7,405
Total assets				513,621
Accounts payable				1,974
Accrued expenses				9,819
Deferred revenue, current				5,989
Operating lease liabilities, current				6,617
Operating lease liabilities, non-current				63,558
Deferred revenue, non-current				24,316
Deferred income taxes				80,537
Other non-current liabilities				13,888
Total liabilities				206,698
Net assets acquired				306,923
Estimated Merger Consideration				1,424,836
Estimated goodwill attributable to Merger				1,117,913
Escrow deposit				2,875
Indemnification liability				$ 9,600
Measurement period adjustment on escrow asset	$ (1,013)
Measurement period adjustment on indemnification liability	$ (3,383)
Unrealized loss on fair value adjustment of escrow asset		$ (2,277)

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired (Details) - Iora $ in Thousands	Sep. 01, 2021USD ($)
Business Acquisition [Line Items]
Preliminary Fair Value	$ 363,031
Medicare Advantage contracts - existing geographies
Business Acquisition [Line Items]
Preliminary Fair Value	$ 298,000
Estimated Useful Life (in years)	9 years
CMS Direct Contracting contract - existing geographies
Business Acquisition [Line Items]
Preliminary Fair Value	$ 52,000
Estimated Useful Life (in years)	9 years
Trade name: Iora
Business Acquisition [Line Items]
Preliminary Fair Value	$ 13,031
Estimated Useful Life (in years)	3 years

Business Combinations - Adjustm

Business Combinations - Adjustments to Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Net loss	$ 90,859	$ 39,318
Transaction costs
Business Acquisition [Line Items]
Net loss		(3,237)
Amortization and depreciation expenses
Business Acquisition [Line Items]
Net loss		11,541
Stock-based compensation costs
Business Acquisition [Line Items]
Net loss		698
Change in tax effects
Business Acquisition [Line Items]
Net loss		$ (4,909)

Business Combinations - Unaudit

Business Combinations - Unaudited Pro Forma (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 183,620
Net Loss	$ (62,374)

Business Combinations - Loan Ag

Business Combinations - Loan Agreement (Details) - Iora - Credit Facility $ in Thousands	Sep. 01, 2021USD ($)
Business Acquisition [Line Items]
Debt assumed and repaid	$ 5,391
Debt prepayment penalty	$ 50

Business Combinations - Other A

Business Combinations - Other Acquisitions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)business_acquired	Mar. 31, 2022USD ($)
Business Acquisition [Line Items]
Goodwill	$ 1,147,464	$ 1,145,094
Customer relationships \| Minimum
Business Acquisition [Line Items]
Useful life	3 years
Customer relationships \| Maximum
Business Acquisition [Line Items]
Useful life	7 years
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Number of acquisitions \| business_acquired	3
Cash consideration	$ 9,908
Goodwill	5,880
Series of Individually Immaterial Business Acquisitions \| Customer relationships
Business Acquisition [Line Items]
Acquired intangibles	$ 3,921

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	3 Months Ended
Goodwill and Intangible Assets - Goodwill (Details)	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairments	$ 0
Goodwill [Roll Forward]
Balance as of December 31, 2021	1,147,464,000
Measurement period adjustments	(2,370,000)
Balance as of March 31, 2022	$ 1,145,094,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets and Accumulated Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangibles	$ 0
Finite-Lived Intangible Assets [Line Items]
Original Cost		$ 366,952	$ 366,952
Accumulated Amortization		(25,752)	(14,794)
Net Book Value		341,200	352,158
Medicare Advantage contracts - existing geographies
Finite-Lived Intangible Assets [Line Items]
Original Cost		298,000	298,000
Accumulated Amortization		(19,315)	(11,037)
Net Book Value		278,685	286,963
CMS Direct Contracting contract - existing geographies
Finite-Lived Intangible Assets [Line Items]
Original Cost		52,000	52,000
Accumulated Amortization		(3,370)	(1,926)
Net Book Value		48,630	50,074
Trade name: Iora
Finite-Lived Intangible Assets [Line Items]
Original Cost		13,031	13,031
Accumulated Amortization		(2,534)	(1,448)
Net Book Value		10,497	11,583
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Original Cost		3,921	3,921
Accumulated Amortization		(533)	(383)
Net Book Value		$ 3,388	$ 3,538

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Future Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 32,876
2023	43,835
2024	42,356
2025	39,417
2026	39,417
Thereafter	143,299
Net Book Value	$ 341,200	$ 352,158

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Details) - Convertible Senior Notes Due 2025 $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	May 31, 2020USD ($)Tradingday$ / sharesshares	Mar. 31, 2022USD ($)shares	Mar. 31, 2021shares	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Face amount \| $	$ 275,000			$ 41,250
Interest rate	3.00%	3.00%		3.00%
Proceeds from debt offering \| $	$ 306,868
Convertible conversion amount \| $	$ 1
Debt converted to common stock (in shares) \| shares	22.5052000	7,117,000	7,117,000
Debt instrument conversion price (in usd per share) \| $ / shares	$ 44.43
Number of threshold trading days	20
Number of consecutive trading days	30
Conversion percentage	130.00%
Number of trading days observation period	40
Debt instrument, repurchase price percentage	100.00%
Debt issuance costs \| $		$ 9,374
Effective interest rate		0.65%
Conversion Scenario One
Debt Instrument [Line Items]
Number of threshold trading days	20
Number of consecutive trading days	30
Conversion percentage	130.00%
Conversion Scenario Two
Debt Instrument [Line Items]
Convertible conversion amount \| $	$ 1
Number of consecutive trading days	10
Number of business days	5
Percentage applied to product of common stock price and conversion rate	98.00%

Convertible Senior Notes - Summ

Convertible Senior Notes - Summary of Net Carrying Amount of Liability Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 316,250	$ 316,250
Unamortized issuance costs	(5,937)	(6,406)
Net carrying amount	$ 310,313	$ 309,844

Convertible Senior Notes - Su_2

Convertible Senior Notes - Summary of Interest Expense Recognized Related to Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Contractual interest expense	$ 2,372	$ 2,372
Amortization of issuance costs	469	469
Total interest expense related to the 2025 Notes	$ 2,841	$ 2,841

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Incentive Plan, Additional Information (Details) - 2020 Equity Incentive Plan - shares shares in Thousands	1 Months Ended
	Jan. 31, 2020	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grants		2,950
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Term of options granted	10 years
Common Stock Reserve Auto Increase
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of number of shares of common stock outstanding	4.00%

Stock-Based Compensation - 2020

Stock-Based Compensation - 2020 Employee Stock Purchase Plan, Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 36,919	$ 26,328
2020 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period	six-month
Number of shares available for future grants	4,246,000
Stock based compensation expense	$ 425	$ 621

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Options
Outstanding as of beginning of period (in shares)	28,312
Granted (in shares)	1,819
Exercised (in shares)	(579)
Canceled (in shares)	(444)
Outstanding as of end of period (in shares)	29,108	28,312
Number of Options, Options exercisable as of end of period (in shares)	12,146
Number of Options, Option vested and expected to vest as of end of period (in shares)	18,893
Weighted- Average Exercise Price
Outstanding as of beginning of period (in usd per share)	$ 19.32
Granted (in usd per share)	12.11
Exercised (in usd per share)	3.86
Canceled (in usd per share)	15.51
Outstanding as of end of period (in usd per share)	19.24	$ 19.32
Weighted-Average Exercise Price, Options exercisable (in usd per share)	5.95
Weighted-Average Exercise Price, Options vested and expected to vest (in usd per share)	$ 8.60
Weighted-Average Remaining Contractual Term (Years), Outstanding	7 years 5 months 26 days	7 years 6 months 25 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable	6 years 29 days
Weighted-Average Remaining Contractual Term (Years), Options vested and expected to vest	6 years 9 months 29 days
Aggregate Intrinsic Value, Outstanding	$ 79,748	$ 192,955
Aggregate Intrinsic Value, Options exercisable	71,253
Aggregate Intrinsic Value, Options vested and expected to vest	$ 79,303

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Options, Additional information (Details) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)shares	Mar. 31, 2021USD ($)	Dec. 31, 2020trancheshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to service-based options	$ 24,640	$ 17,897
Weighted-average period over which unrecognized compensation cost is expected to be recognized	1 year 7 months 6 days	1 year 10 months 24 days
Fair value of options granted	$ 11,598	$ 12,168
Granted (in shares) \| shares	1,819
Stock based compensation expense	$ 36,919	26,328
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) \| shares			8,645
Number of tranches \| tranche			4
Vesting period			7 years
Achievement of pre-determined increases, period			90 days
Aggregate stock-based compensation expense if service-based vesting conditions are met	197,469
Stock based compensation expense	14,089	$ 14,926
Unamortized stock-based compensation expense	$ 122,863

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumed Equity Awards (Details) - USD ($) $ in Thousands	Sep. 01, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense		$ 36,919	$ 26,328
Assumed Equity Plan \| Equity Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of assumed awards	$ 60,856
Common stock and stock options assumed	52,662
Stock based compensation expense	$ 8,194

Stock-Based Compensation - Tran

Stock-Based Compensation - Tranches of Performance Stock Option (Details) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) \| $ / shares	$ 55
Number of Options (in shares) \| shares	1,330
Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) \| $ / shares	$ 70
Number of Options (in shares) \| shares	1,995
Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) \| $ / shares	$ 90
Number of Options (in shares) \| shares	2,660
Tranche 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) \| $ / shares	$ 110
Number of Options (in shares) \| shares	2,660

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Details) - 2020 Plan - Restricted Stock Unit shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares
Unvested and outstanding as of beginning of period (in shares) \| shares	3,249
Granted (in shares) \| shares	4,693
Vested (in shares) \| shares	(434)
Canceled and forfeited (in shares) \| shares	(292)
Unvested and outstanding as of end of period (in shares) \| shares	7,216
Grant Date Fair Value
Unvested and outstanding as of beginning of period (in usd per share) \| $ / shares	$ 27.90
Granted (in usd per share) \| $ / shares	11.78
Vested (in usd per share) \| $ / shares	31.76
Canceled and forfeited (in usd per share) \| $ / shares	17.78
Unvested and outstanding as of end of period (in usd per share) \| $ / shares	$ 17.60

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 36,919	$ 26,328
Tax benefits related to stock based awards	1,938	30,394
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	943	1,023
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 35,976	$ 25,305

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ (6,732)	$ 4,199
Effective income tax rate	6.90%	(12.00%)
Income tax benefit from change in valuation allowance	$ 6,745

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss	$ (90,859)	$ (39,318)
Denominator:
Weighted average common shares outstanding — basic (in shares)	193,019	136,516
Net loss per share — basic (in usd per share)	$ (0.47)	$ (0.29)
Weighted average common shares outstanding — diluted (in shares)	193,019	136,516
Net loss per share — diluted (in usd per share)	$ (0.47)	$ (0.29)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	1 Months Ended	3 Months Ended
	May 31, 2020	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		43,837,000	35,124,000
Convertible Senior Notes Due 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt converted to common stock (in shares)	22.5052000	7,117,000	7,117,000
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		29,108,000	26,160,000
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		7,207,000	1,847,000
Shares held in special indemnity escrow account in connection with Iora acquisition
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		405,000	0

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended
Commitments and Contingencies (Details) $ in Thousands	May 31, 2018Plaintiff	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of plaintiffs \| Plaintiff	2
Litigation liabiity		$ 11,500
Insurers committed amount		5,950
Litigation settlement amount		$ 5,550

Note Receivable (Details)

Note Receivable (Details) - USD ($) $ in Thousands	Sep. 01, 2021	Jun. 21, 2021
Iora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan advances	$ 30,253
Iora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding		$ 30,000
Maturity period following the earliest of certain maturity dates in the SVB Facility		90 days
Interest rate on notes receivable		10.00%
Iora \| Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding		$ 75,000